Ask AI
Improving Outcomes in Pediatric Patients with AD

CE / CME

From Flare to Control in Atopic Dermatitis: Improving Outcomes in Pediatric Patients With Moderate to Severe Disease

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 27, 2025

Expiration: June 26, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126:417-428.e2.
  2. Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70:836-845.
  3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721.
  4. Weidinger S, Simpson EL, Silverberg JI, et al. Burden of atopic dermatitis in paediatric patients: an international cross-sectional study. Br J Dermatol. 2024;190:846-857.
  5. Silverberg NB, Silverberg, JI. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis. 2015;96:359-361.
  6. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345-360.
  7. Artusa S, Mazzuca G, Piacentini G, et al. Paediatric atopic dermatitis: the unexpected impact on life with a specific look at the molecular level. Int J Mol Sci. 2024;25:4778.
  8. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338-351.
  9. Eichenfield LF, Stripling S, Fung S, et al. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs. 2022;24:293-305.
  10. Napolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35:e15901.
  11. Sugerman DT. JAMA patient page. Atopic eczema. JAMA. 2014;311:636.
  12. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.
  13. Hanifin JM, Baghoomian W, Grinich E, et al. The Eczema Area and Severity Index-a practical guide. Dermatitis. 2022;33:187-192.
  14. International Eczema Council. Investigator Global Assessment Scale. eczemacouncil.org/investigator-global-assessment-scale. Accessed June 25, 2025.
  15. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90:e43-e56.
  16. Crisaborole [prescribing information]. New York, NY: Pfizer; 2023.
  17. Roflumilast [prescribing information]. Westlake Village, CA: Arcutis  Biotherapeutics, Inc; 2024.
  18. Ruxolitinib [prescribing information]. Wilmington, DE: Incyte Corporation; 2024.
  19. Tapinarof [prescribing information]. Long Beach, CA: Dermavant Sciences Inc; 2024.
  20. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;8:e1-e20.
  21. Chovatiya R, Silverberg JI. Iatrogenic burden of atopic dermatitis. Dermatitis. 2022;33:S17-S23.
  22. Sreeraj K, Risana, VU, Mathew SR, et al. Optimized and safe use of topical corticosteroids in pediatric dermatology through interdisciplinary collaboration: a review. Discover Medicine. 2024;1:15.
  23. Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev. 2022;3:CD013356.
  24. Anderson P, Austin J, Lofland JH, et al. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11:1571-1585.
  25. UpToDate. Management of severe, refractory atopic dermatitis (eczema) in children. uptodate.com/contents/management-of-severe-refractory-atopic-dermatitis-eczema-in-children. Accessed June 25, 2025.
  26. Eichenfield LF, Boguniewicz M, Lauren CT, et al. Systemic therapy for atopic dermatitis in children and adolescents: A US expert consensus. Dermatology. 2024;240:897-909.
  27. Butala S, Castelo-Soccio L, Seshadri R, et al. Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations. J Allergy Clin Immunol Pract. 2023;11:1361-1373.
  28. Dupilumab [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2023.
  29. Tralokinumab-ldrm [prescribing information]. Madison, NJ: LEO Pharma Inc.; 2024.
  30. Lebrikizumab-lbkz [prescribing information]. Indianapolis, IN; Eli Lilly and Company; 2025.
  31. Nemolizumab-ilto [prescribing information]. Dallas, TX: Galderma Laboratories, L.P.; 2024.
  32. Abrocitinib [prescribing information]. New York, NY: Pfizer; 2023.
  33. Upadacitinib [prescribing information]. North Chicago, IL: AbbVie Inc.; 2023.
  34. Flohr C, Cork MJ, Ardern-Jones MR, et al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatolog Treat. 2023;34:2200866.
  35. Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149:977-987.e14.
  36. Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9:e16704.
  37. Mikhaylov D, Ungar B, Renert-Yuval Y, et al. Oral Janus kinase inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130:577-592.
  38. Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189:531-539.
  39. Hoy SM. Baricitinib: a review in moderate to severe atopic dermatitis. Am J Clin Dermatol. 2022;23:409-420.
  40. Silverberg JI, Bissonnette R, Kircik L, et al. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). J Eur Acad Dermatol Venereol. 2023;37:1366-1374.
  41. Guttman-Yassky E, Simpson E, Bissonnette R, et al. ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 2025;17:83-94.
  42. childhealthbc.ca/sites/default/files/Atopic%20Dermatitis%20Action%20Plan.pdf
  43. Excellence in Motivational Interviewing. Understanding motivational interviewing. motivationalinterviewing.org/understanding-motivational-interviewing. Accessed June 25, 2025.